Abstract
Cost-Effectiveness of Vedolizumab as a First-Line Advanced Therapy Versus Adalimumab Treatment Sequences for Ulcerative Colitis in Italy
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have